Finally, we examined the synergistic antitumor effect of tumor cell-targeted PDT and a long-acting TRAIL variant, i.e., IgBD-TRAIL, that could bind endogenous IgG 28 in mice bearing tumor grafts of CRC cells with chemotherapeutic MDR and TRAIL resistance. The gene discussed is TNFSF10; the disease is neoplasm.